T Heller1, P Ganesh1,2, J Gumulira1, L Nkhoma1, C Chipingu3, C Kanyama4, T Kalua5, R Nyrienda5, S Phiri1,6,7, A Schooley3,8. 1. Lighthouse Trust, Lilongwe, Malawi. 2. International Training and Education Center for Health, Department of Global Health, University of Washington, Seattle, WA, USA. 3. Partners in Hope Medical Centre, Lilongwe, Malawi. 4. University of North Carolina Project, Lilongwe, Malawi. 5. Department of HIV and AIDS, Ministry of Health, Lilongwe, Malawi. 6. Department of Medicine, University of North Carolina School of Medicine, Chapel Hill, NC, USA. 7. Department of Public Health, College of Medicine, School of Public Health and Family Medicine, University of Malawi, Blantyre, Malawi. 8. Department of Medicine, Division of Infectious Disease, David Geffen School of Medicine at the University of California, Los Angeles, CA, USA.
Abstract
SETTING: Malawi has an extensive national antiretroviral treatment (ART) program, and although less than 2% of all patients receive second-line ART, there are increasingly more patients failing on these regimens. OBJECTIVE: To establish a virtual ART committee using limited available local facilities and expertise to recommend third-line regimens based on genotype resistance of samples sent abroad. DESIGN: A secretariat and a laboratory sample hub were established. The committee started work after locally organizing training courses. Decisions about ART regimens were mainly based on a relatively simple, previously described algorithm, which allowed decisions to be taken without extensive expert knowledge. RESULTS: Of the 25 applications assessed, 23 samples were sent for resistance testing from June 2017 to April 2018. Major protease inhibitor (PI) resistance was detected in 65% of the samples. PI resistance was found even in patients exposed to PIs for short periods. In particular, patients who received co-administration of PIs and rifampicin frequently showed resistance mutations. CONCLUSION: Third-line ART using genotypic resistance testing and algorithm-based treatment regimens are feasible in low-resource settings. Our model can serve as a base for similar programs initiating programmatic third-line ART in other African countries.
SETTING: Malawi has an extensive national antiretroviral treatment (ART) program, and although less than 2% of all patients receive second-line ART, there are increasingly more patients failing on these regimens. OBJECTIVE: To establish a virtual ART committee using limited available local facilities and expertise to recommend third-line regimens based on genotype resistance of samples sent abroad. DESIGN: A secretariat and a laboratory sample hub were established. The committee started work after locally organizing training courses. Decisions about ART regimens were mainly based on a relatively simple, previously described algorithm, which allowed decisions to be taken without extensive expert knowledge. RESULTS: Of the 25 applications assessed, 23 samples were sent for resistance testing from June 2017 to April 2018. Major protease inhibitor (PI) resistance was detected in 65% of the samples. PI resistance was found even in patients exposed to PIs for short periods. In particular, patients who received co-administration of PIs and rifampicin frequently showed resistance mutations. CONCLUSION: Third-line ART using genotypic resistance testing and algorithm-based treatment regimens are feasible in low-resource settings. Our model can serve as a base for similar programs initiating programmatic third-line ART in other African countries.
Authors: Souleymane Sawadogo; Andreas Shiningavamwe; Clay Roscoe; Andrew L Baughman; Taffa Negussie; Gram Mutandi; Chunfu Yang; Ndapewa Hamunime; Simon Agolory Journal: Open Forum Infect Dis Date: 2018-01-12 Impact factor: 3.835
Authors: Mina C Hosseinipour; Ravindra K Gupta; Gert Van Zyl; Joseph J Eron; Jean B Nachega Journal: J Infect Dis Date: 2013-06-15 Impact factor: 5.226
Authors: F Fily; E Ayikobua; D Ssemwanga; S Nicholas; P Kaleebu; C Delaugerre; E Pasquier; I Amoros Quiles; S Balkan; B Schramm Journal: Trop Med Int Health Date: 2018-10 Impact factor: 2.622
Authors: Jean B Nachega; Jean-Jacques Parienti; Olalekan A Uthman; Robert Gross; David W Dowdy; Paul E Sax; Joel E Gallant; Michael J Mugavero; Edward J Mills; Thomas P Giordano Journal: Clin Infect Dis Date: 2014-01-22 Impact factor: 9.079
Authors: Dorina Onoya; Cornelius Nattey; Eric Budgell; Liudmyla van den Berg; Mhairi Maskew; Denise Evans; Kamban Hirasen; Lawrence C Long; Matthew P Fox Journal: AIDS Patient Care STDS Date: 2017-04-26 Impact factor: 5.078
Authors: Carina Cesar; Bryan E Shepherd; Cathy A Jenkins; Massimo Ghidinelli; Jose Luis Castro; Valdiléa Gonçalves Veloso; Claudia P Cortes; Denis Padgett; Brenda Crabtree-Ramirez; Eduardo Gotuzzo; Valeria Fink; Adriana Duran; Omar Sued; Catherine C McGowan; Pedro Cahn Journal: PLoS One Date: 2014-09-15 Impact factor: 3.240
Authors: Joep J van Oosterhout; Chifundo Chipungu; Lyse Nkhoma; Hope Kanise; Mina C Hosseinipour; Jean Babtiste Sagno; Katherine Simon; Carrie Cox; Risa Hoffman; Kim Steegen; Bilaal W Matola; Sam Phiri; Andreas Jahn; Rose Nyirenda; Tom Heller Journal: Open Forum Infect Dis Date: 2022-04-05 Impact factor: 3.835